Horizon Discovery Share Discussion Threads

[deltrotter] 09/3/2016 16:45

Excellent - thanks ElGordo.

[elgordo] 09/3/2016 16:06

"Horizon Discovery's Richard Vellacott speaks at Biotech Capital Show", 3 March -



I suppose no-one wants their company's CFO to be "exciting", so guess it's a good thing he provides a remarkably downbeat delivery of what is intended to come across as a high growth story.

Also, always interesting to hear a CFO come close to making a share performance prediction, starting around 19.39.

[mamcw] 07/3/2016 15:13

Feels that way, especially with a broker share price target so much higher

[nurdin] 07/3/2016 11:33

Looks like that. Could wooosh on any good news..

[deltrotter] 04/3/2016 15:34

Looks like a breakout here....

[jugu] 04/3/2016 09:24

Anyone go to biotech briefing yesterday, Any thoughts?

[deltrotter] 04/3/2016 08:22

Lot of news out yesterday and today about immunotherapy and cancer as the next big thing.

[deltrotter] 02/3/2016 20:44

Investor Briefing from yesterday:

[deltrotter] 02/3/2016 16:31

The gaffer speaks:



Also:

Panmure Gordon have a GBX 270.00 target on the stock. The target means a potential upside of 78.81% from Horizon Discovery Group Plc (LON:HZD)’s last stock price. This rating was released in a research report on 2 March.

[mamcw] 02/3/2016 09:26

So they seem to be creating a JV with the aim of bringing in external funders as soon as the results show promise, with the end game being to sell the JV to one of the majors. Given the fairly dismal share price performance of Horizon since listing, this seems to be a sensible way of trying to attract external money, whilst continuing to leverage their IP platform, although it makes me wonder why they don't just take the whole company private...

[deltrotter] 02/3/2016 08:37

Agreed too.

[small crow] 02/3/2016 08:31

Agreed - a good space to be in.

[blueball] 02/3/2016 07:38

This mornings RNS is very impressive.

[mirandaj] 26/2/2016 07:42

Popularity
The newest of the three main gene-editing tools, CRISPR–Cas9, has spread far and wide. Massachusetts-based Addgene, a non-profit plasmid repository that distributes CRISPR–Cas9 editing kits to 83 countries, sends the largest proportion of its kits to US researchers.

CRISPR-Cas9 gene editing - how it works:


"Horizon has licensed CRISPR IP from Harvard University, the Broad Institute and ERS Genomics with the goal of being able to ensure that we will be able to offer uninterrupted use of this technology to our customers."

[andya99] 26/2/2016 01:20

Brian Burke, Director, Business Development, Horizon Diagnostics presenting at World CDx in London on 16th March:-

Controlling Chaos in Oncology Testing:
• Oncology testing is critical in the fight against cancer and
the ever increasing number of biomarkers and testing
modalities continue to drive complexity
• How do we continue to successfully develop drugs and
supporting diagnostics while maintaining quality outcomes
for patients?

[nurdin] 19/2/2016 10:45

Dont be so easy on him..we all need a scapegoat! :o)

[cestnous] 19/2/2016 10:43

Don't worry Mirabeau, we all make our own decisions. You are providing info not Tips. I'm underwater here and it is very nice of you to offer to accept the blame. :¬)

[mirabeau] 19/2/2016 05:27

I must admit to pangs of guilt for setting this thread up when one considers the poor price performance. I hope no one's lost significant monies.

Anyway, this is from today's DM and reveals HZD's promising future.

Good fortune holders

---

'UP from a January low of 125p, shares of Horizon Discovery advanced 6.5p to 148p after Panmure Gordon’s analyst Mike Mitchell advised clients that its technology platform and strategic positioning makes the business one of the most interesting UK-quoted life sciences companies in the market.

The strategic positioning of the company is unparalleled and the current share price is a compelling entry point for investors. January 2015’s high was 237p.'

[cestnous] 18/2/2016 13:07

We need to get through 150 to see any decent progress.

[deltrotter] 18/2/2016 12:13

On Thursday Panmure Gordon reiterated its broker consensus on shares of Horizon Discovery Group Plc (LON:HZD) giving the company a ‘Buy’ rating.

Panmure Gordon gave shares of Horizon Discovery Group Plc a price target of 270 indicating a potential increase of 81.21% from Horizon Discovery Group Plc’s current price of 149.

[andrewbaker] 17/2/2016 17:14

Horizon is a small and risky business in which to invest, but it is the most likely one that I know of which will greatly benefit from the CRISPR-Cas9 gene editing technique. Other businesses are out there, but many are not quoted. We should be in for a good run north in the share price due to recent permissions to gene edit human tissue, but like all cutting edge new technologies still looking for a killer application, a close watch should be kept on any holding, as a small disappointment can cause a big drop in price. Having said that, a little good news can also cause a big jump in price too; so if you believe, as I do, that bio-tech is one area of great growth potential going forward, buy now whilst the price is still relatively low. All IMHO, DYOR.

[small crow] 17/2/2016 14:00

Stagnant is a polite term for it! Anyway, looks like someone knows something here... and let's hope they are correct.

[nurdin] 17/2/2016 13:19

Yes you are right...i thought breakthroughs like that have a positive effect on sentiment towards the sector as a whole although I note that OXB is relatively stagnant.

[small crow] 17/2/2016 13:02

nurdin

I don't think HZD target that area directly - you want OXB.